Empowered Patient Podcast

Dr. Marc Hedrick, President and CEO of Plus Therapeutics Inc.,  has expanded their focus from glioblastoma to leptomeningeal metastasis, a central nervous system cancer that is a growing challenge due to increased survival rates from primary cancers. Their highly sensitive, advanced diagnostic test, CNSide, can detect cancer cells in cerebrospinal fluid, addressing the shortcomings of imaging and outdated standard-of-care practices. Using AI and advanced data analytics, their lead drug candidate is uniquely suited for treating CNS cancers because its safety at high doses enables the precise delivery of radiation. Marc explains, "Since we last talked and we discussed primarily the use of radiotherapeutics for the treatment of glioblastoma. We've expanded that pretty significantly into a disease called leptomeningeal metastasis. And I think we may have touched on that briefly, at least conceptually, a few years ago. But now it's really real. We've just completed a phase one trial, and we're expanding that with